Pharmaceutical Management Branch/Cancer Therapy Evaluation Program/Division of Cancer Treatment and Diagnosis/National Cancer Institute
6130 Executive Blvd * Suite 7149 * Rockville, Maryland 20852
Phone: (301) 496-5725 * Order fax: (301) 480-4612 * Other fax: (301) 402-0429 * E-mail: pmbafterhours@mail.nih.gov

Question: What should I do when patients return clinical supplies of NCI-supplied investigational agents that were previously dispensed? Should I return them to the NCI Clinical Repository?

Answer: If the protocol is *open label*, destroy the returned clinical supplies locally according to your institution's local destruction policy. You can make a note in the patient's chart and/or on the back of the Drug Accountability Record Form if you want to track the return.

If the protocol is *blinded*, document dispensed clinical supplies (opened and unopened kits, boxes, or bottles) returned by the patient in the patient-specific NCI Investigational Agent Accountability Record (i.e., logged in as 'returned by patient'). Destroy these on site in accordance with institutional policy (i.e., logged out as 'destroyed on site').

In summary, when a patient returns NCI-supplied investigational agent

- **For open label studies:** Destroy all dispensed/returned agent on site.
- **For blinded studies:** Record all dispensed/returned agent on the patient-specific DARF, then destroy it on site.

Patients should return all dispensed, unused agent to the dispensing pharmacy.

Questions regarding return/destruction of clinical supplies can be directed to the Pharmaceutical Management Branch (PMB), CTEP, NCI by calling (301) 496-5725 Monday through Friday from 8:30am to 4:30pm Eastern Time or by emailing "PMBAfterHours@mail.nih.gov" at any time.

September 7, 2008